Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer

Cancer Letters

Volumn 304, Issue 2, 2011, Pages 137-143

  Schulte, Rachael R ^a   Linkous, Amanda G ^b   Hallahan, Dennis E ^c,d,e   Yazlovitskaya, Eugenia M ^a,f  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Washington University in St Louis School of Medicine   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Cytosolic phospholipase A2; Lysophosphatidic acid; Lysophosphatidylcholine; Ovarian cancer; Radiation therapy

Indexed keywords

ARACHIDONYLTRIFLUOROMETHYL KETONE; CYTOSOLIC PHOSPHOLIPASE A2; LYSOPHOSPHATIDIC ACID RECEPTOR; PHOSPHOLIPASE A2 INHIBITOR; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL DEATH; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IONIZING RADIATION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN INDUCTION; RADIATION RESPONSE; RADIOSENSITIZATION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; ARACHIDONIC ACIDS; BLOTTING, WESTERN; COMBINED MODALITY THERAPY; CYTOPLASM; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PHOSPHOLIPASES A2, CYTOSOLIC; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 79952735023     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.02.015     Document Type: Article

References (50)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 2007, 57:43-66.
2. Hennessy B.T., Coleman R.L., Markman M. Ovarian cancer. Lancet 2009, 374:1371-1382.
3. Yap T.A., Carden C.P., Kaye S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat. Rev. Cancer 2009, 9:167-181.
4. Cannistra S.A. Cancer of the ovary. New Engl. J. Med. 2004, 351:2519-2529.
5. Vasey P.A. Ovarian cancer: front-line standard treatment in 2008. Ann. Oncol. 2008, 19(Suppl. 7):vii61-66.
6. Rochet N., Jensen A.D., Sterzing F., Munter M.W., Eichbaum M.H., Schneeweiss A., Sohn C., Debus J., Harms W. Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - pilot trial of a phase I/II study: study protocol. BMC Cancer 2007, 7:227.
7. Mosalaei A., Kazerooni T. Results of post-operative abdomino-pelvic radiotherapy in intermediate- and high-risk epithelial ovarian carcinoma. Eur. J. Cancer Care (Engl.) 2008, 17:371-376.
8. Gadducci A., Cosio S., Conte P.F., Genazzani A.R. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit. Rev. Oncol. Hematol. 2005, 55:153-166.
9. Marsden D.E., Friedlander M., Hacker N.F. Current management of epithelial ovarian carcinoma: a review. Semin. Surg. Oncol. 2000, 19:11-19.
10. Firat S., Murray K., Erickson B. High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes. Int. J. Radiat. Oncol. Biol. Phys. 2003, 57:201-207.
11. Sorbe B. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, Controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int. J. Gynecol. Cancer 2003, 13:278-286.
12. Yazlovitskaya E.M., Linkous A.G., Thotala D.K., Cuneo K.C., Hallahan D.E. Cytosolic phospholipase A2 regulates viability of irradiated vascular endothelium. Cell Death Differ. 2008, 15:1641-1653.
13. Linkous A., Geng L., Lyshchik A., Hallahan D.E., Yazlovitskaya E.M. Cytosolic phospholipase A2: targeting cancer through the tumor vasculature. Clin. Cancer Res. 2009, 15:1635-1644.
14. Bonventre J.V. The 85-kD cytosolic phospholipase A2 knockout mouse: a new tool for physiology and cell biology. J. Am. Soc. Nephrol. 1999, 10:404-412.
15. Chakraborti S. Phospholipase A(2) isoforms: a perspective. Cell Signal. 2003, 15:637-665.
16. Fujita Y., Yoshizumi M., Izawa Y., Ali N., Ohnishi H., Kanematsu Y., Ishizawa K., Tsuchiya K., Tamaki T. Transactivation of fetal liver kinase-1/kinase-insert domain-containing receptor by lysophosphatidylcholine induces vascular endothelial cell proliferation. Endocrinology 2006, 147:1377-1385.
17. Fang X., Gaudette D., Furui T., Mao M., Estrella V., Eder A., Pustilnik T., Sasagawa T., Lapushin R., Yu S., Jaffe R.B., Wiener J.R., Erickson J.R., Mills G.B. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann. NY Acad. Sci. 2000, 905:188-208.
18. Tokumura A., Majima E., Kariya Y., Tominaga K., Kogure K., Yasuda K., Fukuzawa K. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 2002, 277:39436-39442.
19. Mills G.B., Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 2003, 3:582-591.
20. Xie Y., Meier K.E. Lysophospholipase D and its role in LPA production. Cell Signal. 2004, 16:975-981.
21. Yuelling L.M., Fuss B. Autotaxin (ATX): a multi-functional and multi-modular protein possessing enzymatic lysoPLD activity and matricellular properties. Biochim. Biophys. Acta 2008, 1781:525-530.
22. Aoki J., Inoue A., Okudaira S. Two pathways for lysophosphatidic acid production. Biochim. Biophys. Acta 2008, 1781:513-518.
23. Yu S., Murph M.M., Lu Y., Liu S., Hall H.S., Liu J., Stephens C., Fang X., Mills G.B. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J. Natl. Cancer Inst. 2008, 100:1630-1642.
24. Xu Y., Fang X.J., Casey G., Mills G.B. Lysophospholipids activate ovarian and breast cancer cells. Biochem. J. 1995, 309(Pt 3):933-940.
25. Ren J., Xiao Y.J., Singh L.S., Zhao X., Zhao Z., Feng L., Rose T.M., Prestwich G.D., Xu Y. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res. 2006, 66:3006-3014.
26. Fang X., Schummer M., Mao M., Yu S., Tabassam F.H., Swaby R., Hasegawa Y., Tanyi J.L., LaPushin R., Eder A., Jaffe R., Erickson J., Mills G.B. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim. Biophys. Acta 2002, 1582:257-264.
27. Tokumura A., Kume T., Fukuzawa K., Tahara M., Tasaka K., Aoki J., Arai H., Yasuda K., Kanzaki H. Peritoneal fluids from patients with certain gynecologic tumor contain elevated levels of bioactive lysophospholipase D activity. Life Sci. 2007, 80:1641-1649.
28. Goetzl E.J., Dolezalova H., Kong Y., Hu Y.L., Jaffe R.B., Kalli K.R., Conover C.A. Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res. 1999, 59:5370-5375.
29. Fujita T., Miyamoto S., Onoyama I., Sonoda K., Mekada E., Nakano H. Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Lett. 2003, 192:161-169.
30. Nakamoto T., Yasuda K., Yasuhara M., Yoshimura T., Kinoshita T., Nakajima T., Okada H., Ikuta A., Kanzaki H. Expression of the endothelial cell differentiation gene 7 (EDG-7), a lysophosphatidic acid receptor, in ovarian tumor. J. Obstet. Gynaecol. Res. 2005, 31:344-351.
31. Farooqui A.A., Ong W.Y., Horrocks L.A. Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol. Rev. 2006, 58:591-620.
32. Trimble L.A., Street I.P., Perrier H., Tremblay N.M., Weech P.K., Bernstein M.A. NMR structural studies of the tight complex between a trifluoromethyl ketone inhibitor and the 85-kDa human phospholipase A2. Biochemistry 1993, 32:12560-12565.
33. Eder A.M., Sasagawa T., Mao M., Aoki J., Mills G.B. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin. Cancer Res. 2000, 6:2482-2491.
34. Li H., Wang D., Zhang H., Kirmani K., Zhao Z., Steinmetz R., Xu Y. Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice. Mol. Cancer Ther. 2009, 8:1692-1701.
35. Karube H., Nishitai G., Inageda K., Kurosu H., Matsuoka M. NaF activates MAPKs and induces apoptosis in odontoblast-like cells. J. Dent. Res. 2009, 88:461-465.
36. Wadgaonkar R., Somnay K., Garcia J.G. Thrombin induced secretion of macrophage migration inhibitory factor (MIF) and its effect on nuclear signaling in endothelium. J. Cell. Biochem. 2008, 105:1279-1288.
37. Yazlovitskaya E.M., Pelling J.C., Persons D.L. Association of apoptosis with the inhibition of extracellular signal-regulated protein kinase activity in the tumor necrosis factor alpha-resistant ovarian carcinoma cell line UCI 101. Mol. Carcinogen. 1999, 25:14-20.
38. Cui W., Yazlovitskaya E.M., Mayo M.S., Pelling J.C., Persons D.L. Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal-regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. Mol. Carcinogen. 2000, 29:219-228.
39. Linkous A., Yazlovitskaya E. Cytosolic phospholipase A2 as a mediator of disease pathogenesis. Cell. Microbiol. 2010, 12:1369-1377.
40. Godwin A.K., Meister A., O'Dwyer P.J., Huang C.S., Hamilton T.C., Anderson M.E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA 1992, 89:3070-3074.
41. Yazlovitskaya E.M., DeHaan R.D., Persons D.L. Prolonged wild-type p53 protein accumulation and cisplatin resistance. Biochem. Biophys. Res. Commun. 2001, 283:732-737.
42. DeHaan R.D., Yazlovitskaya E.M., Persons D.L. Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase. Cancer Chemother. Pharmacol. 2001, 48:383-388.
43. Persons D.L., Yazlovitskaya E.M., Cui W., Pelling J.C. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin. Cancer Res. 1999, 5:1007-1014.
44. Persons D.L., Yazlovitskaya E.M., Pelling J.C. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J. Biol. Chem. 2000, 275:35778-35785.
45. Xu Y. Sphingosylphosphorylcholine and lysophosphatidylcholine: G protein-coupled receptors and receptor-mediated signal transduction. Biochim. Biophys. Acta 2002, 1582:81-88.
46. Xiao Y.J., Schwartz B., Washington M., Kennedy A., Webster K., Belinson J., Xu Y. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs. nonmalignant ascitic fluids. Anal. Biochem. 2001, 290:302-313.
47. Westermann A.M., Havik E., Postma F.R., Beijnen J.H., Dalesio O., Moolenaar W.H., Rodenhuis S. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann. Oncol. 1998, 9:437-442.
48. Xu Y., Gaudette D.C., Boynton J.D., Frankel A., Fang X.J., Sharma A., Hurteau J., Casey G., Goodbody A., Mellors A., et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin. Cancer Res. 1995, 1:1223-1232.
49. Okita M., Gaudette D.C., Mills G.B., Holub B.J. Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients. Int. J. Cancer 1997, 71:31-34.
50. Wang P., Wu X., Chen W., Liu J., Wang X. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms. Gynecol. Oncol. 2007, 104:714-720.